PURPOSE: The goal of this study was to examine the therapeutic potential of the vascular endothelial growth factor (VEGF) signaling inhibitor cediranib in a human model of renal cell carcinoma (Caki-1). METHODS AND MATERIALS: The effects of cediranib treatment on in vitro endothelial cell function (proliferation, migration, and tube formation), as well as in vivo angiogenesis and tumor growth, were determined. RESULTS: In vitro, cediranib significantly impaired the proliferation and migration of endothelial cells and their ability to form tubes, but had no effect on the proliferation of Caki-1 tumor cells. In vivo, cediranib significantly reduced Caki-1 tumor cell-induced angiogenesis, reduced tumor perfusion, and inhibited the growth of Caki-1 tumor xenografts. CONCLUSIONS: The present results are consistent with the notion that inhibition of VEGF signaling leads to an indirect (i.e., antiangiogenic) antitumor effect, rather than a direct effect on tumor cells. These results further suggest that inhibition of VEGF signaling with cediranib may impair the growth of renal cell carcinoma.
PURPOSE: The goal of this study was to examine the therapeutic potential of the vascular endothelial growth factor (VEGF) signaling inhibitor cediranib in a human model of renal cell carcinoma (Caki-1). METHODS AND MATERIALS: The effects of cediranib treatment on in vitro endothelial cell function (proliferation, migration, and tube formation), as well as in vivo angiogenesis and tumor growth, were determined. RESULTS: In vitro, cediranib significantly impaired the proliferation and migration of endothelial cells and their ability to form tubes, but had no effect on the proliferation of Caki-1tumor cells. In vivo, cediranib significantly reduced Caki-1tumor cell-induced angiogenesis, reduced tumor perfusion, and inhibited the growth of Caki-1tumor xenografts. CONCLUSIONS: The present results are consistent with the notion that inhibition of VEGF signaling leads to an indirect (i.e., antiangiogenic) antitumor effect, rather than a direct effect on tumor cells. These results further suggest that inhibition of VEGF signaling with cediranib may impair the growth of renal cell carcinoma.
Authors: James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Neil R Smith; Neil H James; Ian Oakley; Anna Wainwright; Clive Copley; Jane Kendrew; Lynsey M Womersley; Juliane M Jürgensmeier; Stephen R Wedge; Simon T Barry Journal: Mol Cancer Ther Date: 2007-08 Impact factor: 6.261
Authors: Tianli Wang; Rajneet K Oberoi; William F Elmquist Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2011-10-29 Impact factor: 3.205
Authors: Thu P Huynh; Sonali P Barwe; Seung J Lee; Ryan McSpadden; Omar E Franco; Simon W Hayward; Robert Damoiseaux; Stephen S Grubbs; Nicholas J Petrelli; Ayyappan K Rajasekaran Journal: PLoS One Date: 2015-04-02 Impact factor: 3.240